Three names across three sectors, on the strongest market-regime reading in two weeks. The regime score rose to 70, the threshold for a full list, but every leading sector is still losing speed and fewer than a third carry positive momentum, so the list stays capped at three. For the first time in a week the shortlist is not all Energy: a product tanker, a semiconductor maker and a cancer-therapy biotech.
The core scan, signal screener, breakout list and sector table all refreshed this morning. The gem list and the defined-risk spread screener still carry yesterday's data, so no spread structures are shown. This page was published later than usual today; the data underneath it is from this morning.
| Sector | Momentum | Accel | 1D | Read |
|---|---|---|---|---|
| Shipping · BOAT | +12.80 | −23.74 | +2.08% | Still first; bid again today |
| Cloud · SKYY | +7.70 | −30.89 | +1.37% | Second |
| Software · IGV | +6.26 | −17.68 | +0.28% | Third |
| Commodities · DBC | +5.17 | −14.39 | −0.51% | Fading |
| AI · AIQ | +2.99 | −13.52 | +1.94% | New to the top five |
| Energy · XLE | +2.45 | −14.09 | −0.02% | Out of the top five for the first time this month |
| Semiconductors · SOXX | −1.95 | −20.51 | +3.18% | Best day in the table, from negative momentum |
The top Stage 2 score in the market today and the only name on all three candidate lists. It sits in Shipping, still the fastest sector, and has Mansfield RS +27.2 with SATA 10 on both timeframes. The catalyst is ownership, not oil: Hafnia is buying 4.5M shares to lift its stake to about 18%, while Oaktree sold down, widening the U.S. holder base. Counter-evidence: RSI 73.8; it is already the second-best pick in the book since August 31st (+14.6% vs SPY), so this is a second observation of a name that has run; hedge-fund signal is weak; and a 12% dividend yield usually means the market prices the cycle as temporary.
Mansfield RS +51.6, 63 weeks into Stage 2, after a record fiscal second quarter and a run of target raises tied to AI data-center and IoT demand. It rallied 7.7% today with semiconductors (+3.2%), and it is the only finalist whose analyst target sits well above the price. The least overbought of the three at RSI 65. Counter-evidence: its sector has negative momentum and is decelerating hard (−20.5), so this is a rebound inside a weak group; relative strength fell this week (−2.8); SATA is 8, not 10; a price-to-earnings multiple of about 91; and today's move came within a whisker of the 8% same-day veto.
The strongest relative strength in the scan by a distance — Mansfield RS +139, rising 22.7 this week — on all three candidate lists, 40 weeks into Stage 2. Barclays lifted its target to $15 this morning on physician-survey support for its cell therapy in second-line lung cancer. Read the caveats first, which is why this card is amber: it is a single-program biotech with a lung-cancer data update due in Q4, a binary event that can move the stock either way far more than any trend signal; it is up 262% this year; RSI is 77.4; it trades above the average analyst target; and it rose 7.5% today, just under the same-day veto.
None has a fresh timing crossover; all three sit outside the 157-name universe that scan covers.
The defined-risk spread screener still carries yesterday's rows, so no spread is shown as if it were live.
| Cohort | Mean alpha | Median | Beat SPY | Best | Worst |
|---|---|---|---|---|---|
| 2026-08-31 · 7 | +4.48% | −0.17% | 3/7 | CVI +29.7% | ESTC −10.9% |
| 2026-09-01 · 7 | −0.62% | −0.87% | 3/7 | VLO +13.7% | SLB −13.3% |
| 2026-09-02 · 3 | −8.28% | −9.61% | 0/3 | VET −4.5% | HP −10.7% |
| 2026-09-03 · 3 | −1.74% | −2.26% | 1/3 | CRGY +2.6% | ZYME −5.6% |
| 2026-09-08 · 3 | −2.36% | −1.98% | 0/3 | ELPC −0.0% | MTDR −5.1% |
| 2026-09-11 · 3 | +6.78% | +5.33% | 3/3 | TEN +14.3% | UROY +0.7% |
| 2026-09-15 · 3 | −4.17% | −2.92% | 0/3 | SUN −1.6% | SM −8.0% |
| 2026-09-16 · 2 | +0.76% | +0.76% | 2/2 | MPC +1.1% | LPG +0.4% |
| All 31 | −0.03% | −1.56% | 12/31 | trimmed −0.77% · ex top two −1.56% | |
Total alpha across 31 picks is −0.8 points, while CVI (+29.7) and TRMD (+14.6) together contribute +44.3. Without them the other 29 average −1.56%. Yesterday's two picks both beat SPY on day one; the day before's three all trailed it. One session is not evidence either way.